Personalis Inc
NASDAQ:PSNL

Watchlist Manager
Personalis Inc Logo
Personalis Inc
NASDAQ:PSNL
Watchlist
Price: 6.09 USD 2.35%
Market Cap: 430.3m USD
Have any thoughts about
Personalis Inc?
Write Note

Personalis Inc
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Personalis Inc
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Personalis Inc
NASDAQ:PSNL
Net Income (Common)
-$91.4m
CAGR 3-Years
-16%
CAGR 5-Years
-33%
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Net Income (Common)
$6.1B
CAGR 3-Years
-11%
CAGR 5-Years
11%
CAGR 10-Years
14%
Danaher Corp
NYSE:DHR
Net Income (Common)
$3.9B
CAGR 3-Years
-12%
CAGR 5-Years
10%
CAGR 10-Years
4%
Mettler-Toledo International Inc
NYSE:MTD
Net Income (Common)
$795.6m
CAGR 3-Years
2%
CAGR 5-Years
8%
CAGR 10-Years
9%
Agilent Technologies Inc
NYSE:A
Net Income (Common)
$1.3B
CAGR 3-Years
2%
CAGR 5-Years
4%
CAGR 10-Years
9%
IQVIA Holdings Inc
NYSE:IQV
Net Income (Common)
$1.4B
CAGR 3-Years
22%
CAGR 5-Years
42%
CAGR 10-Years
15%
No Stocks Found

Personalis Inc
Glance View

Market Cap
430.2m USD
Industry
Life Sciences Tools & Services

Personalis, Inc. engages in the provision of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The company is headquartered in Menlo Park, California and currently employs 325 full-time employees. The company went IPO on 2019-06-20. The firm is focused on the development of therapies by providing molecular data about each patient's cancer and immune response. The company provides sequencing and data analysis services to support the development of cancer therapies. Its NeXT Platform, which provides its biopharmaceutical customers with information on over 20,000 human genes, together with the immune system, in contrast to many cancer panels that cover over 50 to 500 genes. Its NeXT Platform is designed to provide analysis of both a tumor and its immune microenvironment from a single limited tissue sample. Its platform covers the deoxyribonucleic acid sequence of all of the approximately 20,000 human genes. The company also reports on transcriptome of a tumor, which encompasses ribonucleic acid expression across human genes, allowing it to determine which of the genomic mutations might actually be driving tumor progression.

PSNL Intrinsic Value
1.97 USD
Overvaluation 68%
Intrinsic Value
Price

See Also

What is Personalis Inc's Net Income (Common)?
Net Income (Common)
-91.4m USD

Based on the financial report for Sep 30, 2024, Personalis Inc's Net Income (Common) amounts to -91.4m USD.

What is Personalis Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-33%

Over the last year, the Net Income (Common) growth was 19%. The average annual Net Income (Common) growth rates for Personalis Inc have been -16% over the past three years , -33% over the past five years .

Back to Top